Experimental shot targets deadly brain tumors in early trial
NCT ID NCT07497373
First seen Apr 03, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This early-phase study tested a single injection of JL15003 in 17 adults whose glioblastoma brain cancer had come back after standard treatment. The main goal was to check safety and find the best dose, while also watching for signs of tumor shrinkage and how long patients lived. The trial is complete, and results will help plan a larger study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME(GBM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
-
Huashan Hospital, Shanghai Medical College, Fudan University
Shanghai, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.